Showing results (1-10 of 36) with videos related to
Sort By:
Pageof 4
European Journal of Clinical Pharmacology|March 4, 2021
Repositioning HIV protease inhibitors and nucleos(t)ide RNA polymerase inhibitors for the treatment of SARS-CoV-2 infection and COVID-19Nils von HentigDrugs of Today (Barcelona, Spain : 1998)|April 5, 2008
Atazanavir/ritonavir: a review of its use in HIV therapyNils von HentigDrugs of Today (Barcelona, Spain : 1998)|April 27, 2007
Lopinavir/ritonavir: appraisal of its use in HIV therapyNils von HentigHIV/AIDS (Auckland, N.Z.)|January 6, 2016
Clinical use of cobicistat as a pharmacoenhancer of human immunodeficiency virus therapyNils von HentigDrugs of Today (Barcelona, Spain : 1998)|October 17, 2009
A review of current literature on second-generation, sucrose-formulated, full-length recombinant factor VIIIChristoph Konigs, Nils von HentigAntimicrobial Agents and Chemotherapy|June 17, 2009
Cytochrome P450 3A inhibition by atazanavir and ritonavir, but not demography or drug formulation, influences saquinavir population pharmacokinetics in human immunodeficiency virus type 1-infected adultsNils von Hentig, Jörn LötschExpert Review of Clinical Pharmacology|November 6, 2012
Safety of pharmacoenhancers for HIV therapyNils von Hentig, Annette HaberlAntiviral Therapy|February 5, 2008
Predictive factors for response to a boosted dual HIV-protease inhibitor therapy with saquinavir and lopinavir in extensively pre-treated patientsNils von Hentig, Errol Babacan, Schlomo Staszewski, et al.Antimicrobial Agents and Chemotherapy|April 16, 2008
Decrease of atazanavir and lopinavir plasma concentrations in a boosted double human immunodeficiency virus protease inhibitor salvage regimenNils von Hentig, Pavel Kaykhin, Christoph Stephan, et al.European Journal of Clinical Pharmacology|August 1, 2007
Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adultsNils von Hentig, Brenda Dauer, Annette Haberl, et al.Pageof 4